GlassScriptPhysician profile
Charles E Fuenzalida
NPI 1730175688
$29,942.80
in general payments reported to CMS, 2019-2025
42 companies · $4,097 in 2025
The $4,097 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $1,403 · 2021: $887 · 2022: $6,005 · 2023: $6,551 · 2024: $9,538 · 2025: $4,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $2,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,325.00 |
| Food and Beverage | $2,860.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $20,497.88 | 2020-2025 | Carto 3 |
| Boston Scientific Corporation | $2,366.31 | 2019-2023 | Watchman Access System |
| Biosense Webster, INC. | $1,902.83 | 2020-2025 | Carto 3 |
| Medtronic, INC. | $483.25 | 2021-2023 | Onyx Frontier, Telescope |
| Impulse Dynamics (USA) INC. | $378.62 | 2021-2024 | Optimizer |
| Sanofi-Aventis U.S. LLC | $377.96 | 2019-2024 | |
| Pfizer INC. | $365.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $323.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $315.47 | 2019-2024 | Xarelto |
| Abbott Laboratories | $256.89 | 2019-2023 | Jot Dx |
| Cvrx, INC. | $251.34 | 2023 | Barostim Neo System |
| Heartflow, INC. | $237.93 | 2024-2025 | |
| Novo Nordisk INC | $206.15 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $182.31 | 2021-2025 | Amvuttra |
| Amgen INC. | $178.59 | 2019-2025 | Repatha, Repatha |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Fuenzalida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.